关键词: 社会责任, 研发创新, 医药供应链, 组合契约

Abstract: Based on the perspective that the pharmaceutical manufacturer and medical institution pay attention to consumer surplus at the same time, this paper, taking research and development innovation and medical insurance payment as endogenous factors that affect consumer utility, depicts the impact of social responsibility on equilibrium results in different decision-making models. The research shows that whether it is the whole pharmaceutical supply chain or the pharmaceutical manufacturers’ individual focus on social responsibility, it is beneficial to enhance the research and development innovation ability in the three kinds of decision-making models. In the non-cooperative decision-making model, enhancing the social responsibility of the pharmaceutical manufacturer can effectively control the wholesale and retail prices of drugs, increase the income of stakeholders and the surplus value of consumers, but it will weaken its own profitability. However, as the overall social responsibility of the supply chain increases, improving the level of social responsibility shared within the threshold is conducive to the value-added of the pharmaceutical manufacturer. The combination contract coordination strategy consisting of government subsidies, collaborative innovation, and collective procurement optimizes the pharmaceutical supply chain, which can effectively stimulate the power of innovation and increase overall social welfare.

Key words: social responsibility, research and development innovation, pharmaceutical supply chain, combination contract